Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis

John E. Feliciano-Alfonso¹, Juliana Muñoz-Ortiz²,³, María Alejandra Marín-Noriega², Andrés Vargas-Villanueva², Laura Triviño-Blanco², Natalia Carvajal-Saiz² and Alejandra de-la-Torre²*

Abstract

Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, which leads to visual impairment in a large proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual loss by controlling infection and inflammation. However, there remains disagreement regarding optimal antibiotic therapy for OT. Therefore, this systematic review and meta-analysis were performed to determine the effects and safety of existing antibiotic treatment regimens for OT.

Methods: MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials, LILACS, WHO International Clinical Trials Registry Platform portal, ClinicalTrials.gov, and Gray Literature in Europe (“OpenGrey”) were searched for relevant studies; manual searches of reference lists were performed for studies identified by other methods. All published and unpublished randomized controlled trials that compared antibiotic schemes known to be effective in OT at any dosage, duration, and administration route were included. Studies comparing antibiotics with placebo were excluded. This review followed standard methodological procedures recommended by the Cochrane group.

Results: Ten studies were included in the narrative summary, of which four were included for quantitative synthesis (meta-analysis). Interventions were organized into three groups: intravitreal clindamycin versus pyrimethamine + sulfadiazine, trimethoprim + sulfamethoxazole versus other antibiotics, and other interventions. The first comparison favored intravitreal clindamycin (Mean difference (MD) = 0.10 logMAR; 95% confidence interval = 0.01 to 0.22). However, this finding lacks clinical relevance. Other outcomes showed no statistically significant differences between the treatment groups. In general, the risk of performance bias was high in evaluated studies, and the quality of the evidence found was low to very low.

Conclusions: No antibiotic scheme was superior to others, and the selection of a treatment regimen depends on multiple factors; therefore, treatment should be chosen based on safety, sulfa allergies, and availability.

Keywords: Toxoplasmosis, ocular, Toxoplasma gondii, Uveitis, Anti-bacterial agents, Therapeutics

Background

Ocular toxoplasmosis (OT) is a primary cause of posterior uveitis worldwide, particularly in South America [1, 2]. OT results from an acquired or congenital infection by the obligate intracellular protozoan parasite Toxoplasma gondii (Tg), which can infect both humans and animals. An estimated 25%–30% of the human population is infected with Tg [3]. Seroprevalence is low (approximately 10%–30%) in Southeast Asia, Northern Europe, and North America. In Central and Southern
Europe, the prevalence reported varies between 30 and 50%. Latin America and some tropical countries in Africa have higher seroprevalence (up to 80%) [4].

*P. gondii* infection in humans can be congenital or post-natally acquired through contaminated hands, food, water, consumption of undercooked and raw meat, organ transplantation, blood transfusion, or vertical transmission [5–7]. Toxoplasmosis has a variety of clinical manifestations in humans. Congenital toxoplasmosis is associated with intrauterine growth restriction, neurological, mental disease, hydrocephalus, encephalitis, retinochoroiditis, hearing and cardiovascular abnormalities, and fetal loss; it may also be asymptomatic [8, 9]. Acquired infection is asymptomatic in more than 80% of immunocompetent patients. In contrast, 20% of infected individuals may experience ocular compromise, fever, or cervical lymphadenopathy; these manifestations are occasionally associated with myalgia, asthenia, or other nonspecific clinical signs [10].

The most common manifestation of OT is toxoplasmic retinochoroiditis, which typically comprises a unilateral, unilateral, necrotizing retinochoroidal lesion that appears as a whitish-yellow region with a blurred margin, with or without an accompanying old lesion (often associated with vitritis) [11].

The treatment goals in OT are reducing the risk of visual impairment by avoiding the multiplication of the parasite during the active stage of retinochoroiditis, and diminishing the necrotizing inflammation and subsequent harm to adjacent tissues [12]. In addition, because antibiotic treatment is only effective against the tachyzoite form of the parasite, it is important to treat each active lesion, which presumably reduces the risk of recurrence [12, 13].

Antibiotic therapy in acute lesions of OT is highly recommended for the reduction of intraocular inflammation and the prevention of retinal and optic disc damage. Unfortunately, current treatment schemes do not eradicate *P. gondii* tissue cysts; thus, they do not prevent further reactivation of toxoplasma retinochoroiditis unless prophylaxis is started [14].

Various treatment regimens are often used in clinical practice. The classic triple therapy is pyrimethamine + sulfadiazine (PYR/SDZ) combined with folinic acid, which is the first choice for congenital toxoplasmosis and immunosuppressed patients; PYR/SDZ + clindamycin + folinic acid is known as quadruple therapy; trimethoprim + sulfamethoxazole (TMP/SMX) can be used alone or combined with clindamycin; for individuals allergic to sulfa, azithromycin + pyrimethamine + folinic acid or clindamycin + pyrimethamine + folinic acid can be used; and clindamycin alone can be used for intravitreal therapy [14]. In addition, corticosteroids can be used as an adjuvant treatment. Oral prednisolone at 1 mg/kg/day is administered from the third day until 2–6 weeks of treatment. Intravitreal therapy also includes clindamycin combined with dexamethasone [15].

In survey studies, ophthalmologists were asked about the therapies they used to manage active OT; the results revealed a diverse range of treatment regimens, and many ophthalmologists expressed doubtfulness about questions regarding the disease. The diversity of responses suggests widespread uncertainty regarding appropriate treatment for this disease; moreover, there is a need for continuing medical education regarding OT [16]. There have been some publications concerning this topic [13, 17, 18]. Notably, a systematic review of the literature was published in 2003 regarding antibiotics for toxoplasmic retinochoroiditis; however, it compared antibiotic schemes versus placebo and concluded that there was a lack of evidence to support routine antibiotic treatment [18]. Another systematic review compared antibiotic treatment versus placebo in patients with OT; it found a lack of evidence to support routine antibiotic treatment for toxoplasma retinochoroiditis to prevent visual impairment and found weak evidence regarding the prevention of recurrences. Thus, the authors of that study concluded that the risk of recurrence is likely reduced after long-term treatment with systemic antibiotics [13]. Nonetheless, in ophthalmological clinical practice, antibiotic treatment must be provided to achieve treatment objectives for patients with OT. Our systematic review and meta-analysis will complement a recently published meta-analysis regarding treatment in immunocompetent patients [19].

This systematic review and meta-analysis aimed to evaluate the evidence-based information regarding the safety and efficacy of different existing antibiotic regimens in patients with OT worldwide.

**Methods**

**Protocol and registration**

The study protocol was developed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) guidelines [20], and it was previously published in 2019 [21]. In the same way, it was registered in PROSPERO, with the registration number CRD42018085468 [22].

**Eligibility criteria**

We included all published and unpublished randomized controlled trials (RCTs) comparing therapies that have been used in OT. RCTs provide the highest quality of evidence according to the grading of recommendation assessment, development, and evaluation (GRADE) classification [23, 24]. Therapies described in the literature for
OT include trimethoprim-sulfamethoxazole, pyrimethamine, sulfaadoxine, clindamycin, tetracyclines, clarithromycin, azithromycin, atovaquone, minocycline, spiramycin, rifabutin, trimetrexate, lincomycin, dapsone, sulfafurazole, ciprofloxacin, doxycycline, minocamycin, erythromycin, macrolide, sulfonamide, sulfamerazine, nifurtimox, methotrexate, alone or in combination [13, 25–28]. We also included therapies at any dosage, duration, and administration route, oral or intravitreal. RCTs comparing antibiotics with placebo were excluded because a systematic review of this comparison has already been conducted by Pradhan et al. [13]. Participants included were patients of any age who received antibiotic treatment for acute OT worldwide, and those with healed scars who received prophylactic antibiotic treatment to prevent recurrent or new lesions, including immunocompetent patients, immunosuppressed patients, pregnant women, and children.

Outcomes
Primary outcome measures were changes in visual acuity at least three months after the start of treatment and the number of recurrences at the end of follow-up. Secondary outcome measures included the behavior of ocular inflammation signs according to the Standardization of Uveitis Nomenclature (SUN), size of lesion at the end of the follow-up, adverse drug reactions, and duration of the active lesion, as stated in the study protocol [21].

Information sources
We used a combination of exploded controlled vocabulary with thesaurus Science Health Descriptors (DeCS for its Spanish acronym), Medical Subject Heading (MeSH) and Embase Subject Headings (Emtree), and free-text terms (considering spelling variants, plurals, synonyms, acronyms, and abbreviations) with field labels, truncation, proximity operators, and Boolean operators. We conducted our search in the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and LILACS electronic databases, from inception to March 2018 (Annex 1). Besides, the search was updated in November 2020. For identification of additional studies, the following resources were used: WHO International Clinical Trials Registry Platform portal, ClinicalTrials.gov, Gray Literature in Europe (“OpenGrey”), and manual searches within reference lists of all relevant studies identified by other methods.

Study selection
Studies obtained by electronic databases were independently reviewed by two authors (JFA and AVV), evaluating titles and abstracts of all studies. Next, they independently compared the full text with the inclusion criteria. Finally, disagreements were resolved by consensus or by a third reviewer (ADLT).

Data collection process
A data collection form was designed. Then, two review authors (IMO and JFA) independently extracted relevant details regarding the design and results of each study. Disagreements were resolved by consensus or by independent evaluation by a third review author (ADLT). One review author (JFA) entered data into Review Manager 5.3 (RevMan 5.3) software and a third reviewer (ADLT) checked them to ensure data quality.

Risk of bias in individual studies
We used the Cochrane group “Risk of Bias” tool for RCTs and criteria in the Cochrane Handbook for Systematic Reviews of Interventions to assess these risks in the relevant domains of the reported methods and results from each included study. The five domains are selection bias, performance bias, attrition bias, detection bias, reporting bias, and other biases. These domains can be classified as high, unclear, and low risk of bias [29].

Dichotomous data
We presented the results as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data.

Continuous data
We used the mean difference for continuous data if outcomes were measured in the same manner among multiple trials. We used the standardized mean difference to combine trials that measured the same outcome using different methods.

Management of missing data
We contacted study investigators to obtain missing data. We analyzed available data without making assumptions or imputing data to adjust for missing data.

Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using the I² statistic. We regarded heterogeneity as substantial if I² was >40% and <70%, which required using a random-effects model in the analysis. If there was substantial heterogeneity and I² was >70%, meta-analysis was not performed; instead, a narrative summary of data was conducted.
Assessment of reporting biases
We used funnel plots to assess publication bias when at least 10 studies were available for meta-analysis. In addition, we evaluated possible sources of asymmetry in funnel plots, following the method described in the Cochrane Handbook for Systematic Reviews of Interventions [29].

Data synthesis
We used a random-effects model to calculate our meta-analysis if eligible studies represented clinically varied populations. In addition, we used a fixed-effect meta-analysis for combining data where it was reasonable to assume that studies estimated the same underlying treatment effect. Statistical analysis using RevMan 5.3 and GRADE assessment (Annex 2) was performed by one author (JFA). We assessed statistical heterogeneity in each meta-analysis using the I² statistic. Additional information about the methodology is presented in the published protocol [21].

Results

Literature search results
In total, 131 studies were identified in the electronic databases (44 in Embase, 43 in MEDLINE, 32 in Cochrane Central Register of Controlled Trials, and 12

---

**Fig. 1** Study flow diagram

| March 2018 | November 2020 |
|------------|--------------|
| Records identified through database searching<br> MEDLINE: 43<br> Embase: 44<br> Cochrane: 32<br> LILACS: 12<br> Additional sources: 18 | Records identified through database searching<br> update<br> MEDLINE: 7<br> Embase: 11<br> Cochrane: 3<br> LILACS: 0 |
| Records after duplicate removal<br> n = 106 | Records excluded (did not meet the inclusion criteria)<br> n = 91 |
| Records screened based on title and abstract<br> n = 106 | Records excluded<br> n = 5 |
| Assessed for eligibility<br> n = 15 | No full-text available: Abreu 1988<br> Non-Randomized Controlled Trials: Jedd 1997, Prasil 2014, Raskin 2002<br> Sub-study: Sadoughi 2006 (Soheilian 2005) |
| Full-text evaluation<br> n = 15 | Balaskas 2012, Baharvand 2013, Bosch-Driessen 2002, Colin 1989, Ghanizadeh 2017, Kartasasmita 2017, Lashay 2017, Ortega 2000, Soheilian 2005, Soheilian 2011 |
| Records included for qualitative synthesis<br> n = 10 | Beharvand 2013, Lashay 2017, Soheilian 2005, Soheilian 2011 |
| Records included for quantitative synthesis<br> n = 4 | |
in LILACS); 18 references were identified in the additional sources. After duplicates had been removed, 94 records were screened; 15 were selected for full-text evaluation. Five studies were excluded for reasons indicated in Fig. 1 [30–35]. In the case of Sadoughi et al. 2006 study [35], the same population was also evaluated by Soheilian 2005; thus, we choose the study with a longer follow-up, which corresponded to Soheilian 2005 [30].

The remaining 10 studies were included for narrative summary of data (Balaskas 2012 [36], Baharivand 2013 [37], Bosch-Driessen 2002 [38], Colin 1989 [39], Ghavidel 2017 [40], Kartasasmita 2017 [41], Lashay 2017 [42], Ortega 2000 [43], Soheilian 2005 [30], Soheilian 2011 [44]); four provided sufficient information for quantitative synthesis (meta-analysis) (Baharivand 2013 [37], Lashay 2017 [42], Soheilian 2005 [30], Soheilian 2011 [44]).

In the update 2020, 21 new studies were identified in the electronic databases (11 in Embase, 7 in MEDLINE, 3 in Cochrane Central Register of Controlled Trials, and 0 in LILACS). After duplicates had been removed, 12 records were screened. None of the studies evaluated in the title and abstract phase met the selection criteria.

Characteristics of included studies
Most of the 10 included studies were conducted in Asia, particularly in Iran (Baharivand 2013 [37], Ghavidel 2017 [40], Lashay 2017 [42], Soheilian 2005 [30], Soheilian 2011 [44]) and Indonesia (Kartasasmita 2017 [41]). The remaining studies were conducted in Europe (Balaskas 2012 [36], Bosch-Driessen 2002 [38], Colin 1989 [39]) and North America (Ortega 2000 [43]). All 10 studies were published between 1989 and 2017. Eight studies used the classic therapy PYR/SDZ as a comparison group. Three studies included patients under 18 years of age (Colin 1989 [39], Ortega 2000 [43], Soheilian 2005 [30]); patient age ranged between 7 and 72 years in all included studies. In general, the studies had a small sample size, from 19 patients (Balaskas 2012 [36]) to 72 patients (Ghavidel 2017 [40]). A summary of all included studies can be found in Table 1, and Annex 3 provides detailed information regarding the 10 included studies.

Risk of bias
Overall, nine studies had a high risk of performance bias; seven studies had low risks of selection bias (random sequence generation), detection bias, and other bias. The Ortega 2000 [43] study had a high risk of bias in most attributes; the Soheilian 2005 [30] study did not have a high risk of bias in any evaluated attributes. The bias risk assessments for all included studies are summarized in Figs. 2 and 3.

It was not possible to assess the publication bias since the number of studies necessary to evaluate it was not enough.

Effects of interventions
**Intravitreal clindamycin versus PYR/SDZ**

The number of studies that provided data for this comparison was two RCT, and both were included in the meta-analysis. The Soheilian 2011 [44] and Baharivand 2013 [37] studies compared head-to-head intravitreal clindamycin versus PYR/SDZ. Regarding changes in visual acuity, the meta-analysis revealed statistically significant differences in favor of intravitreal clindamycin (mean difference = 0.11 logMAR; 95% CI = 0.03 to 0.20) (Fig. 4). However, this result is not considered clinically relevant, as will be discussed below. Additionally, in the random-effects model, there were no statistically significant differences (MD 0.10 logMAR; 95% CI = -0.01 to 0.22). No significant differences were reported in the two studies regarding the number of recurrences and lesion size. In the Soheilian 2011 [44] study, lesion size was reported in pixels with a mean percentage of changes of 1.4% (95% CI = -14.6% to 17.4%, p = 0.86). In contrast, in the Baharivand 2013 [37] study, retinal lesion size was reported as ≤1 disc area (DA), <1 and ≤2 DA, and <2 and ≤3 DA. Baharivand et al. [37] regarded improvement in retinal lesion size as a lesion size that decreased in terms of DA classification (improvement of 65.6% intravitreal clindamycin group versus 67.6% in PYR/SDZ group, p = 0.86). Although none of the studies reported ocular inflammation according to the SUN, this outcome was evaluated as a reduction of vitreous cells to the level of 0 or trace after treatment, which was regarded as the resolution of vitreous inflammation. Thus, for this outcome, there was no statistical heterogeneity ($I^2 = 0$%), and no significant differences were found between the treatment groups (RR = 1.04; 95% CI = 0.83 to 1.31) (Fig. 5).

In the Baharivand 2013 study, the arm that evaluated intravitreal clindamycin presented no adverse drug reactions, whereas in the PYR/SDZ arm, one case of adverse drug reactions was reported (hepatotoxicity). In the Soheilian 2011 study, there were two cases of adverse drug reactions in the PYR/SDZ arm (skin rash and thrombocytopenia), which were not included in the efficacy analysis, while in the intravitreal clindamycin arm, there were four cases of adverse drug reactions (three subconjunctival hemorrhages and one transient raised intraocular pressure).
| Author, year | Location     | Participants | Intervention Treatment | Control Treatment | Outcomes | Intervention | Control |
|-------------|--------------|--------------|------------------------|-------------------|----------|--------------|----------|
| Balaskas, 2012 | Switzerland  | N= 19        | Azithromycin + prednisone | PYR/SDZ + folinic acid + prednisone | Changes in VA | NR          | NR       |
|             |              | Intervention = 10 | Administration route: oral | Administration route: oral | Number of recurrences | NR | NR |
|             |              | Control = 9 | | | Improvement in VA | NR | NR |
|             |              | | | | Ocular inflammation | NR | NR |
|             |              | | | | Retinal lesion size | NR | NR |
|             |              | | | | Adverse drug reactions (minor) | NR | 9 (100%) |
| Baharivand, 2013 | Iran         | N= 66        | Clindamycin + dexamethasone | PYR/SDZ + folinic acid + prednisone | Changes in VA | 0.38 ± 0.35 logMAR | 0.35 ± 0.29 logMAR |
|             |              | Intervention = 32 | Administration route: intravitreal | Administration route: oral | Number of recurrences | 4 (12.5%) | 5 (14.7%) |
|             |              | Control = 34 | | | Improvement in VA (gaining ≥ 2 Snellen lines) | 27/32 | 28/34 |
|             |              | | | | Ocular inflammation (grade 0/trace) | 28 (87.5%) | 28 (82.4%) |
|             |              | | | | Retinal lesion size improvement | 21 (65.6%) | 23 (67.6%) |
|             |              | | | | Adverse drug reactions (major) | 0 | 1 (2.9%) |
| Bosch-Driessen, 2002 | Netherlands | N= 46        | PYR + Azithromycin + folinic acid + prednisone | PYR/SDZ + folinic acid + prednisone | Changes in VA | NR | NR |
|             |              | Intervention = 24 | Administration route: oral | Administration route: oral | Number of recurrences (at least one year follow up) | 5/15 (33%) | 5/9 (56%) |
|             |              | Control = 22 | | | Improvement in VA (≥ 0.5 logMAR units at 3 months) | 5/24 (21%) | 5/18 (28%) |
|             |              | | | | Ocular inflammation (No inflammatory cells from vitreous within 4 w) | 14/20 (70%) | 10/14 (71%) |
|             |              | | | | Retinal lesion size improvement (decrease more than 0.5 optic disk diameter in 3 months) | 9/22 (41%) | 7/17 (41%) |
|             |              | | | | Adverse drug reactions (all) | 8/24 (33%) | 14/22 (64%) |
## Table 1 (continued)

| Author, year | Location | Participants | Intervention Treatment | Control Treatment | Outcomes | Intervention | Control |
|--------------|----------|--------------|------------------------|-------------------|----------|--------------|---------|
| Colin, 1989  | Not exactly reported | N= 29, Intervention = 14, Control = 15 | Clindamycin Administration route: subconjunctival injections + oral prednisolone | PYR/SDZ + Prednisolone Administration route: oral Folinic acid Administration route: Intramuscular | Changes in VA NR Ocular inflammation NR Improvement in VA NR Retinal lesion Size NR Number of recurrences 21% Adverse drug reactions (all) 1 | | |
| Ghavidel, 2017 | Iran | N= 72, Intervention = 36, Control = 36 | Azithromycin + prednisolone Administration route: oral | PYR/SDZ + prednisolone Administration route: oral | Changes in VA NR Ocular inflammation NR Improvement in VA NR Number of recurrences (during 24 months after treatment) 18 (50%) Retinal lesion size (reduction during treatment) 354.86 µm Adverse drug reactions (all) 4 (12.5%) | | |
| Kartasasmita, 2017 | Indonesia | N= 28, Intervention = 14, Control = 14 | TMP/SMX + Clindamycin + methylprednisolone + folic acid Administration route: oral | PYR/SDZ + methylprednisolone Administration route: oral | Changes in VA NR Number of recurrences NR Improvement in VA NR Ocular inflammation NR Adverse drug reactions NR Retinal lesion size (percentage of lesion area reduction in the third w) 57.50% | | |
| Lashay, 2017 | Iran | N= 27, Intervention = 14, Control = 13 | Azithromycin + prednisone Administration route: oral | TMP/SMX + Prednisone Administration route: oral | Changes in VA 0.24 ± 0.04 logMAR Ocular inflammation (vitreous inflammatory cells clearance) 7 (50%) Retinal lesion size (reduction) 24.2% ± 6.5% Adverse drug reactions (mild) 4 (28.5%) | 0.30 ± 0.01 logMAR Ocular inflammation (vitreous inflammatory cells clearance) 10/14 Retinal lesion size (reduction) 36.6% ± 4.6% Adverse drug reactions (mild) 3 (23%) | |
| Author, year | Location | Participants | Intervention | Control | Outcomes | Intervention | Control |
|--------------|----------|--------------|--------------|---------|----------|--------------|---------|
| Ortega, 2000 | Mexico   | N=46         | G1 TMP/SMX+PYR+Prednisone+folinic acid | -       | Changes in VA | NR          | -       |
|              |          | Intervention G1 = 13 | G2 TMP/SMX+Clindamycin+Prednisone Administration route: oral | Improvemnt in VA | NR         | -              |         |
|              |          | Intervention G2 = 22 | G3 TMP/SMX+PYR+Clindamycin+Prednisone+folinic acid Administration route: oral | Ocular inflammation | NR         | -              |         |
|              |          | Intervention G3 = 11 |                           | Retinal lesion size | NR         | -              |         |
|              |          |                           |                                           | Number of relapses | G1 1 (7.6%) | G2 5 (31.2%) |         |
|              |          |                           |                                           |                      | G3 4 (36.3%) |              |         |
|              |          |                           |                                           | Adverse drug reactions | (called "Complications from treatment" and apparently mild) | G1 1 (7.6%) | G2 4 (18.1%) | G3 0 (0%) |
| Soheilian, 2005 | Iran    | N=59         | TMP/SMX+oral prednisolone Administration route: oral | Improvement in VA (increase) | 0,52 logMAR | 0,56 logMAR |         |
|              |          | Intervention = 30 | PYR/SDZ+folinic acid+prednisolone Administration route: oral | Changes in VA | NR |                  |         |
|              |          | Control = 29 |                           | Number of recurrences | 3 (10%) | 3 (10,3%) |         |
|              |          |                           |                                           | Ocular inflammation | 17 (56,7%) | 20 (69%) |         |
|              |          |                           |                                           | Retinal lesion size | (mean reduction 6 w after treatment) | 59% | 61% |         |
|              |          |                           |                                           | Retinal lesion size | (calculated in pixels using MATLAB environment) | 116,994+—143,997 Pixels | 89,606+—651,553 pixels |         |
| Soheilian, 2011 | Iran    | N=68         | Clindamycin+dexamethasone Administration route: intravitreal | Improvement in VA | 1*31 (2,8%) | 1*30 (2,9%) |         |
|              |          | Intervention = 34 | PYR + SDZ + folinic acid + prednisolone Administration route: oral | Changes in VA | 0,44±0,24 logMAR | 0,29±0,19 logMAR |         |
|              |          | Control = 34 |                           | Number of recurrences | 2 | 2 |         |
|              |          |                           |                                           | Ocular inflammation | (trace or no vitreous cells) | 15 (51,7%) | 15 (55,5%) |         |
|              |          |                           |                                           | Retinal lesion size | (calculated in pixels using MATLAB environment) | 116,994+—143,997 Pixels | 89,606+—651,553 pixels |         |
|              |          |                           |                                           | Adverse drug reactions | (all) | 4/34 | 2*36 |         |

PYR Pyrimethamine, SDZ Sulfadiazine, TMP/SMX trimethoprim/sulfamethoxazole, N Total sample, NR Not reported, VA Visual Acuity, w: weeks. * Patients excluded from the study. See details in Annex 3.
**TMP/SMX versus another antibiotic**

Two RCTs compared TMP/SMX versus another antibiotic, and both were included in the meta-analysis. The Soheilian 2005 and Lashay 2017 [42] studies compared TMP/SMX versus PYR/SDZ and TMP/SMX versus azithromycin, respectively. In terms of ocular inflammation, regarded as the percentage of patients with a reduction of vitreous inflammatory cells (0 or trace cells) after treatment, there were no significant differences (RR = 1.08; 95% CI = 0.59 to 1.98) with moderate heterogeneity (I² = 66%) (Fig. 6). Likewise, both treatments showed a similar number of adverse drug reactions that ranged from mild to significant. A summary of the results can be found in Table 1. Annex 3 provides detailed information.

**Other interventions**

Six out of ten studies included data about other therapeutic schemes, and none were included in the meta-analysis.

The Kartasasmita 2017 [41] study compared TMP/SMX + oral clindamycin versus PYR/SDZ for 3 weeks and found that the mean percentage of lesion remission from the first visit to the last visit was 57.5% in the first group, while it was 52.5% in the second group (p = 0.72). This result was obtained by comparing the reduction in retinal lesion size between the pretreatment evaluation and the third week of treatment evaluation. However, in the first week of treatment, the authors found that the mean percentage of patients with lesion remission was higher in the TMP/SMX + oral clindamycin group than in the PYR/SDZ group (71.7% versus 19.8%; p = 0.001). There were no safety considerations in this study.

The Ghavidel 2017 [40] study compared azithromycin versus PYR/SDZ for 6 weeks. The authors reported that visual acuity improved by 0.35 logMAR in the azithromycin group and 0.39 logMAR in the PYR/SDZ group, although this difference was not statistically significant (p = 0.33). In addition, there was no difference in the size of the retinal lesion detected. In terms of safety, only four patients in the azithromycin group had gastrointestinal adverse drug reactions. For the PYR/SDZ group, 20 patients presented adverse drug reactions (16 gastrointestinal and 4 dizziness) (p < 0.01 compared with the azithromycin group); however, no severe adverse drug reactions were observed, such as bone marrow suppression.

The Bosch-Driessen 2002 [38] study compared pyrimethamine + azithromycin (PYR/AZ) versus PYR/SDZ for 4 weeks. This study did not report explicit baseline data for included patients. There were no significant differences in visual acuity improvement at 3 months, as well as in the number of recurrences to the first year of treatment or the disappearance of inflammatory cells from vitreous within 4 weeks. The frequency of adverse drug reactions was higher in the PYR/SDZ group than in the PYR/AZ group (64% versus 33%, respectively; p = 0.04); more patients discontinued treatment in the PYR/SDZ group (14%), compared with the PYR/AZ group (0%) (p = 0.1).

The Balaskas 2012 [36] study compared azithromycin with PYR/SDZ in 19 patients without a specific duration of treatment, with a follow-up of 3 months. This study investigated changes in lesion size, time of the sharpening of lesion borders, time to scarring, and time to disease inactivity in days; these results did not demonstrate statistically significant differences. Skin rash was observed in one patient in the PYR/SDZ group. Treatment failure was documented in one patient in the azithromycin group.

The Colin 1989 [39] study compared subconjunctival injections of clindamycin (3 weeks of treatment) versus PYR/SDZ (6 weeks of treatment) in 29 patients. The
authors reported visual acuity but did not specify the measurement units or whether they represented near or far visual acuity. At 14 months after treatment, there were 21% recurrences in the clindamycin group and 36% in the PYR/SDZ group \((p\)-value not reported). In the PYR/SDZ group, one patient exhibited Stevens-Johnson syndrome, and another patient exhibited a skin rash. In the clindamycin group, one patient exhibited corneal ulceration with inflammation.

The Ortega 2000 [43] study was an RCT with three treatment groups: TMP/SMX + PYR versus TMP/SMX + clindamycin versus TMP/SMX + PYR + clindamycin for 8 weeks. All groups exhibited an increase in visual acuity \((p<0.05)\) compared with baseline. Notably, only the TMP/SMX + clindamycin group required less time to resolve inflammation \((p=0.044)\) and achieve healing \((p=0.016)\). Although there were adverse drug reactions, these were not reported explicitly. Table 1 synthesized the results of the included studies in this systematic review.

**Discussion**

**Agreements and disagreements with other studies or reviews**

Our meta-analysis showed that, when comparing the effectiveness of intravitreal clindamycin and oral PYR/SDZ, there were significant differences in visual acuity in favor of intravitreal clindamycin (Fig. 4). However, there were no clinically significant differences in the use of either treatment because the changes in visual acuity corresponded to 0.1 logMAR (i.e., one line in the Snellen chart). Significant changes in visual acuity are defined as worsening or gaining \(\geq 15\) letters (i.e., three lines in standardized optotypes) [45, 46]. It is important to highlight the findings of the meta-analysis by Pradhan et al. in 2016 [13], where only one study (Felix et al. 2014) [47] evaluated visual acuity outcome measured at least 3 months after the start of treatment, showing similar changes in the TMP/SMX and placebo groups [13].

Regarding lesion size, the measurement methods in the included studies did not allow a meta-analytical comparison of the findings. Furthermore, in the meta-analysis by Pradhan et al., the outcome of lesion size was considered, but the analyzed studies did not report it [13]. The methods described in the literature for measuring lesion size include the following: fundoscopic images, in which the lesion and optic disc areas were measured using Photoshop software and the ratio of the lesion to optic disc area was calculated [48]; a program written in the MATLAB environment made to determine the margin of the retinitis and to measure the area of interest in pixels [44]; and the retinal lesion size in terms of \(\leq 1\) disc area (DA), \(< 1\) and \(\leq 2\) DA, and \(< 2\) and \(\leq 3\) DA. “Improvement” was considered a lesion size that decreased in terms of DA classification [37]. It is important to create consensus regarding lesion size measurements and the percentage of lesion reduction in future investigations.

Even though the SUN working group was first published in 2005 [49], intraocular inflammation measures were not used in most of the included studies, and this outcome could not be objectively measured. Therefore, in further studies, the use of this classification is crucial to standardize and compare the intraocular inflammation outcomes.

Concerning the antibiotic interventions evaluating recurrences in OT, it is important to notice that all the regimens of antibiotics were not included in our
systematic review. For example, an observational study performed in patients treated with intensive therapy in the active phase, followed by long-term treatment with pyrimethamine sulfadoxine (PYR/SDX) (it was not included in our review since it was not a RCT), revealed a 90.9% probability of 3-year recurrence-free survival after the first intervention [50]. Future RCTs may include PYR/SDX scheme, as it is one of the alternative therapies accessible in different countries where PYR/SDZ is not available.

Regarding the number of recurrences, there were no statistically significant differences between PYR/SDZ and intravitreal clindamycin in the evaluated studies. Nevertheless, the reduction of recurrences in patients with OT has been evaluated in long-term therapy studies after the acute stage of infection has been controlled. In the meta-analysis by Pradhan et al., the authors found that treatment with antibiotics compared with placebo or no treatment probably reduces the risk of recurrent toxoplasma retinochoroiditis (Risk ratio 0.26, 95% CI 0.11 to 0.63; 227 participants; 3 studies; I² = 0%; moderate-quality evidence).

Additionally, in the meta-analysis by Pradhan et al., there was low-quality evidence regarding visual acuity changes, intraocular inflammation, and adverse drug reactions [13]. This agrees with the results of our meta-analysis, where we found that the evidence quality of the included studies was from low to very low (GRADE methodology results are shown in Annex 2). This means that there are no well-conducted RCTs regarding OT treatment, indicating that further rigorous research is very likely to have an important impact on the confidence of the estimated effect and, in consequence, could change it.

Zhang et al. [19] published a network meta-analysis about treatment in ocular toxoplasmosis. The overall confidence rating of Zhang et al. review is critically low, according to the AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews 2) [51]. Indeed, more than one critical flaw was found in the AMSTAR 2 assessment in domains 2, 7, 9, 13, and 15. Notably, the network meta-analysis of Zhang et al. did not report the risk of bias of the included studies. In contrast, our study accomplishes all the items required in AMSTAR 2, obtaining high overall confidence. Furthermore, our systematic review and meta-analysis provide an accurate and comprehensive summary of the results of the available studies that address the question of interest. Nonetheless, we recognize that although the AMSTAR 2 was not intended to handle the special requirements of a network meta-analysis [51], a modified AMSTAR should be developed to assess network meta-analyses [52]. Recently published papers showed that the tool called CINeMA (Confidence in Network Meta-Analysis) contributes to assessing the credibility of the results of a network meta-analysis and should be taken into account when properly evaluating this type of study design [53, 54]. A comparison of AMSTAR 2 results of our work and Zhang et al.’s study is available in Annex 4.
Regarding the safety of the analyzed drugs, it was found that those studies that reported information on PYR/SDZ adverse drug reaction had a frequency that was in the range of 0.05% (Sohelian 2011 [44]) to 100% (Balaskas 2012 [36]), including all degrees of severity. In the same way, concerning TMP/SMX, adverse drug reaction was reported from 2.8% (Sohelian 2005 [30]) to 23% (Lashay 2017 [42]), and through various degrees of severity. Thus, overall, there were no significant differences in adverse drug reactions for the different treatment regimens compared to each other, except for the azithromycin-containing arms. Indeed, Ghavidel et al. [40] found a better tolerance in the azithromycin group than its comparator, which also occurred in Bosch-Driessen 2002 [38]. Therefore, azithromycin appears to have a better safety profile among the different options analyzed through the studies included in this systematic review.

Finally, according to the results of this systematic review, some combinations of antibiotic schemes have not been compared in clinical trials but are used in the clinical practice. Therefore, we consider that it is crucial to know the results of comparisons between combined clindamycin + TMP / SMX + prednisone versus TMP / SMX + prednisone versus clindamycin + prednisone. Also, quadruple-drug therapies such as TMP / SMX + clindamycin + prednisone versus PYR / SDX + azithromycin + prednisone. We also consider it relevant to compare sulfadiazine and sulfadoxine in well-conducted clinical trials, to understand the superiority or noninferiority between these sulfa drugs in OT.

### Conclusions

In general, the quality of the evidence found was low to very low. Although visual acuity analysis revealed a statistically significant difference in the first comparison of intravitreal clindamycin and oral PYR/SDZ, the result was not clinically relevant. Regarding the remaining outcomes, none of them showed statistically significant differences (i.e., no treatments were superior to others). Therefore, the selection of treatment regimen must be performed on an individual basis, considering the safety of each therapeutic regimen, (azithromycin appears to have the best safety profile), medical history of sulfa allergy, and the availability of medications offered within each nation’s health system. Although there is no consensus regarding the best treatment regimens in OT, the treatment should include at least two antibiotics along with corticosteroids.

### Abbreviations
OT: Ocular toxoplasmosis; PYR/SDZ: Pyrimethamine + sulfadiazine; PYR/SDX: Pyrimethamine + sulfadoxine; PYR/AZ: Pyrimethamine + azithromycin; TMP/SMX: Trimethoprim + sulfamethoxazole; SUN: Standardization of Uveitis Nomenclature.

### Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13643-021-01758-7.

### Acknowledgements
We thank Universidad del Rosario for helping us with the manuscript style correction.
Authors' contributions
JEF: Management, research idea, protocol writing, title and abstracts screening, data extraction, manuscript writing, discussion, and meta-analysis. JMO: Protocol writing, data extraction, manuscript writing, discussion, and meta-analysis. AVV: Research idea, protocol registration, title and abstracts screening. LT: Title and abstracts screening, and full-text reading. ADLT: Management, research idea, protocol writing, manuscript writing, discussion, and thematic authority. The author(s) read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author, ADLT, upon reasonable request.

Declarations
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia. 2 NeURos Research Group, Escuela de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia. 3 Escuela Superior de Oftalmología-Instituto Barraquer de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.

Received: 6 March 2020   Accepted: 2 July 2021
Published online: 19 July 2021

References
1. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1–13.
2. Huang PK, Jianping C, Vasconcelos-Santos DV, Arruda JSD, Dutta Majumder P, Anthony E, et al. Ocular toxoplasmosis in tropical areas: analysis and outcome of 190 patients from a multicenter collaborative study. Ocul Immunol Inflamm. 2018;26:1289–96.
3. Montoya J, Liesenfeld O. Toxoplasmosis The lancet. 2004;363:1965–76.
4. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39:1585–94.
5. Khan K, Khan W. Congenital toxoplasmosis: An overview of the neurologi- cal and ocular manifestations. Parasitol Int. 2016;67:715–21.
6. Laurence Baril BC Thierry Ancelle, Véronique Goulet, Philippe Thuliez, Véronique Tirard-Fleury. Risk Factors for Toxoplasma Infection about ocular toxoplasmosis. Am J Ophthalmol. 2005;140:724–e1.
7. Cortéz JA, Roncarico Æ, Urbe LG, Cortés-Luna CF, Montoya JG. Approach to ocular toxoplasmosis including pregnant women. Curr Opin Infect Dis. 2019;32:426–34.
8. Manchester, authors: JEF, AVV, LT, LT, ADLT. Ocular toxoplasmosis. In: Dumitrescu RG, Verma M, editors. Cancer Epigenetics Precis Med [Internet]. New York, NY: Springer New York; 2019 [cited 2019 Apr 7]. p. 79–97. Available from: http://link.springer.com/10.1007/978-3-030-03140-4_5
9. de-la-Torre A, Stanley M, Curi A, Jaffe-Guiz-Marín J. Therapy for Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2011;19:314–20.
10. Lunn F, Jones J. Holland GH, Liesegang TJ. Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol. 2005;140:724–e1.
11. Dodds EM. Ocular toxoplasmosis: Clinical presentation, diagnosis and therapy. Focal Points Clin Modul Ophthalmol. 1999;17:10.
12. Casoy J, Nascimento H, Silva LMP, Fernández-Zamora Y, Muccioli C, Dias JR de O, et al. Effectiveness of Treatments for Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2019;1–7.
13. Pradhan E, Bhardari S, Gilbert RE, Stanford M. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev. 2016;CD002218.
14. Vasconcelos-Santos DV. Ocular Toxoplasmosis. In: Dumitrescu RG, Verma M, editors. Cancer Epigenetics Precis Med [Internet]. New York, NY: Springer New York; 2019 [cited 2019 Apr 7]. p. 79–97. Available from: http://link.springer.com/10.1007/978-3-030-03140-4_5
15. de-la-Torre A, Stanley M, Curi A, Jaffe-Guiz-Marín J. Therapy for Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2011;19:314–20.
16. Moher D, Shamseer L, Clarke M, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
17. Feliciano-Alfonso JE, Vargas-Villanueva A, Muñoz-Ortiz J, de-la-Torre A. Antibiotic treatment for ocular toxoplasmosis: a systematic review and meta-analysis: study protocol. Syst Rev [Internet]. 2019;8:146–146. Available from: https://www.ncbi.nlm.nih.gov/pubmed/3121217
18. PROSPERO: International prospective register of systematic reviews [Internet]. [cited 2020 Nov 26]. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=85468
19. Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. The Lancet. 2017;390:415–23.
20. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
21. Wakefield D, Cunningham ET Jr, Jewkes K, Carw flexDG, Zierhut M. Controversies in ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19:2–9.
22. Engstrom RE Jr, Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111:601–10.
23. Gilbert RE, Harden M, Stanford M. Antibiotics versus control for toxo- plasma retinochoroiditis. Cochrane Database Syst Rev. 2002;
24.的优点 of ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19:2–9.
25. Engstrom RE Jr, Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111:601–10.
26. Gilbert RE, Harden M, Stanford M. Antibiotics versus control for toxo- plasma retinochoroiditis. Cochrane Database Syst Rev. 2002;
27. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
28. Wakefield D, Cunningham ET Jr, Jewkes K, Carw flexDG, Zierhut M. Controversies in ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19:2–9.
29. Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Wwww Cochrane-Handb Org 2011;
30. Soheilian M, Sadoughi M-M, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H, et al. Prospective randomized trial of trimethoprim/sulfa methoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112:1876-82.
31. Abreu M, Martins M, Belfort R. Clindamycin versus spiramycin in ocular toxoplasmosis: a randomised double masked study. Arq Bras Oftalmol. 1998;51:26.
32. Judd J, Aziz A., Bouguila H., Kaurouch M., Malouch M., Daghfoos F., et al. Value of clindamycin in the treatment of ocular toxoplasmosis. J Fr Ophthalmol. 1999;20:418.
33. Prasli P, Plisek S, Bostick P [Ocular toxoplasmosis - seeking a strategy for treatment]. Klin Mikolob Profil Infeckn Lek. 2014;20:112–5.
34. Raskin E, Alves M, Eredia G, Raskin A, Ruiz AM. Ocular toxoplasmosis: A comparative study of the treatment with sulfadiazine and pyrimetamine versus sulframethoxazole-trimethoprim. Rev Bras Oftalmol. 2002;61:335–8.
35. Sadoughi M-M, SOHEYLIAN M, Dehghan M-H, Behboudi H, Anisian A, Yazdani S. Short-term results of two treatment regimens versus ocular toxoplasmosis: Trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine. 2006;
36. Balaskas K, Vaudaux J, Boillat-Blanco N, Guex-Crosier Y. Azithromycin versus SulfaDiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit Int Med J Exp Clin Res. 2012;18:CR296.
37. Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol. 2013;33:39–46.
38. Bosch-Driessen LH, Verbraak FD, Suttrop-Schulten MS, van Ruyven RL, Klok AM, Hooy CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:34–40.
39. Colin J, Harie J. Presumed toxoplasmic chorioretinitis: comparative study of treatment with pyrimethamine and sulfadiazine or clindamycin. J Fr Ophtalmol. 1989;12:161–5.
40. Ghavidel LA, Milani AE, Bagheri M. Comparison of azithromycin and pyrimethamine/sulfadiazine treatment in ocular toxoplasmosis in North West of Iran. Crescent J Med Biol Sci. 2017;4:80–4.
41. Kartasasmita A, Muntur WP, Enus S, Iskandar E. Rapid resolution of chorioretinal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis. Exp Clin Res. 2012;18:CR296.
42. Lashay M, et al. A prospective randomized trial of azithromycin versus dexamethasone versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am J Ophthalmol. 2014;157:762–6.
43. Vishnevskia-Dai V, Achiron A, Buhbou O, Berar OV, Musika AA, Elyashiv SM, et al. Chorio-retinal toxoplasmosis: treatment outcomes, lesion evolution and long-term follow-up in a single tertiary center. Int Ophthalmol. 2019;1–11.
44. Group S of UN (SUN) W. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
45. Borkowski PK, Brydak-Godowska J, Basiak W, Switaj K, Zarnowska-Prymek H, Olzynska-Krowicka M, et al. The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence. PLoS Negl Trop Dis. 2016;10:e0004892.
46. Ana Martínez Rubioj JGA. Valoración de la agudeza visual [Internet]. Rev Pediatr Aten Primaria Vol18 No71 Madr. Jul Sep 2016. 2016 [cited 2019 Aug 19]. Available from: http://scielo.isciii.es/pdf/pap/v18n71/1139-7632-pap-18-71-00267.pdf
47. Felix JPJ, Lira RPC, Zacchia RS, Toribio JM, Nascimento MA, Aneta CEL. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Int Ophthalmol. 2014;157:762–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.